
Bausch Health Companies BHC
$ 6.04
0.83%
Quarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Accounts Payables 2011-2026 | BHC
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 719 M | 521 M | 407 M | 337 M | 503 M | 411 M | 365 M | 324 M | 434 M | 398 M | 327 M | 227 M | 158 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 719 M | 158 M | 395 M |
Quarterly Accounts Payables Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 579 M | 642 M | 719 M | 569 M | 515 M | 561 M | 521 M | 486 M | 536 M | 471 M | 407 M | 455 M | 442 M | 407 M | 337 M | 337 M | 337 M | 337 M | 503 M | 503 M | 503 M | 503 M | 411 M | 411 M | 411 M | 411 M | 365 M | 365 M | 365 M | 365 M | 324 M | 324 M | 324 M | 324 M | 434 M | 434 M | 434 M | 434 M | 398 M | 398 M | 398 M | 398 M | 327 M | 327 M | 327 M | 327 M | 227 M | 227 M | 227 M | 227 M | 158 M | 158 M | 158 M | 158 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 719 M | 158 M | 393 M |
Accounts Payables of other stocks in the Drug manufacturers industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
670 K | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
9.57 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
8.25 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.94 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
8.28 M | - | - | $ 754 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
7.33 M | - | - | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
26.1 M | $ 1.19 | 3.48 % | $ 128 M | ||
|
China Pharma Holdings
CPHI
|
225 K | $ 0.61 | -1.46 % | $ 10.7 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
13.9 M | $ 3.9 | 1.56 % | $ 54.8 M | ||
|
Eagle Pharmaceuticals
EGRX
|
19 M | - | -39.89 % | $ 27.7 M | ||
|
Catalent
CTLT
|
361 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
1.78 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 10.91 | -0.27 % | $ 559 M | ||
|
Harrow Health
HROW
|
27.3 M | $ 52.51 | 1.86 % | $ 1.71 B | ||
|
Endo International plc
ENDP
|
94.7 M | - | - | $ 28.9 M | ||
|
Athenex
ATNX
|
33.7 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
9.24 M | $ 4.3 | -0.69 % | $ 267 M | ||
|
Lannett Company
LCI
|
29.7 M | - | 1.15 % | $ 7.11 M | ||
|
Jupiter Wellness
JUPW
|
2.22 M | - | - | $ 33.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
2.6 M | - | - | $ 193 M | ||
|
Pacira BioSciences
PCRX
|
19.1 M | $ 23.39 | 1.21 % | $ 1.08 B | ||
|
Organogenesis Holdings
ORGO
|
28.9 M | $ 4.01 | 2.42 % | $ 528 M | ||
|
PetIQ
PETQ
|
139 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
495 M | $ 14.63 | 0.48 % | $ 2.01 B | ||
|
ProPhase Labs
PRPH
|
5.9 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
17.6 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
1.31 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
4.52 M | $ 0.94 | 1.95 % | $ 21.9 M | ||
|
Relmada Therapeutics
RLMD
|
3.51 M | $ 4.25 | 5.33 % | $ 128 M | ||
|
Tilray
TLRY
|
70.8 M | $ 7.89 | 4.44 % | $ 4.88 B | ||
|
OptiNose
OPTN
|
3.89 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
13.4 M | $ 12.04 | - | $ 855 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
953 K | $ 2.83 | -0.35 % | $ 3.51 M | ||
|
Solid Biosciences
SLDB
|
4.24 M | $ 6.17 | 5.11 % | $ 252 M | ||
|
SCYNEXIS
SCYX
|
7.15 M | $ 0.8 | 3.91 % | $ 38.3 M | ||
|
Tricida
TCDA
|
10 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
3.04 M | $ 2.63 | 6.05 % | $ 355 M | ||
|
TherapeuticsMD
TXMD
|
27 K | $ 2.25 | -1.32 % | $ 23.5 M | ||
|
cbdMD
YCBD
|
1.54 M | $ 0.92 | 0.72 % | $ 3.97 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
1.94 M | - | - | $ 55.5 M | ||
|
Viatris
VTRS
|
1.77 B | $ 16.15 | 1.22 % | $ 19.6 B |